Literature DB >> 32631005

Behçet's Uveitis: Current Diagnostic and Therapeutic Approach

Pınar Çakar Özdal1.   

Abstract

Behçet's disease is a chronic, multisystem inflammatory disorder characterized by relapsing inflammation. Although its etiopathogenesis has not yet been clarified, both the adaptive and innate immune systems, genetic predisposition, and environmental factors have all been implicated. It is more frequent and more severe in males in the third and fourth decades of life. The eye is the most frequently involved organ in the course of the disease. Ocular involvement (Behçet's uveitis) is characterized by bilateral recurrent non-granulomatous panuveitis and occlusive retinal vasculitis. Recurrent inflammatory episodes in the posterior segment may lead to permanent vision loss due to irreversible retinal damage and complications such as macular scarring, macular atrophy, and optic atrophy. Early and aggressive immunomodulatory treatment and the use of biologic agents when needed are crucial for preventing recurrences and improving visual prognosis.

Entities:  

Keywords:  Behçet’s uveitis; biologics; imaging; prognosis; treatment

Year:  2020        PMID: 32631005      PMCID: PMC7338748          DOI: 10.4274/tjo.galenos.2019.60308

Source DB:  PubMed          Journal:  Turk J Ophthalmol        ISSN: 2149-8709


  102 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Genetic association of HLA-A*2601 with ocular Behçet's disease in Japanese patients.

Authors:  Toshikatsu Kaburaki; Mitsuko Takamoto; Jiro Numaga; Hidetoshi Kawashima; Makoto Araie; Yuka Ohnogi; Shinji Harihara; Shoji Kuwata; Fujio Takeuchi
Journal:  Clin Exp Rheumatol       Date:  2010-09-23       Impact factor: 4.473

3.  Lack of association of HLA-B*51 with a severe disease course in Behçet's disease.

Authors:  A Gül; F A Uyar; M Inanc; L Ocal; I Tugal-Tutkun; O Aral; M Koniçe; G Saruhan-Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2001-06       Impact factor: 7.580

Review 4.  Anti-tumor necrosis factor-α therapy in uveitis.

Authors:  Miguel Cordero-Coma; Lucia Sobrin
Journal:  Surv Ophthalmol       Date:  2015-07-09       Impact factor: 6.048

5.  Ocular Manifestations, Conventional Fundus Fluorescein Angiographic Findings, and Relationship Between Angiographic Findings and Visual Acuity in Behçet's Disease.

Authors:  Fatemeh Bazvand; Mohammad Zarei; Nazanin Ebrahimiadib; Reza Karkhaneh; Samaneh Davoudi; Mahyar Soleimanzadeh; Elaheh Sharifian; Ramak Roohipoor; Bobeck S Modjtahedi
Journal:  Semin Ophthalmol       Date:  2016-08-10       Impact factor: 1.975

6.  Fluorescein angiography and visual acuity in active uveitis with Behçet disease.

Authors:  Hyeong Gon Yu; Moon Jung Kim; Frederick Sewoong Oh
Journal:  Ocul Immunol Inflamm       Date:  2009 Jan-Feb       Impact factor: 3.070

7.  Mycophenolate mofetil for the treatment of uveitis.

Authors:  Stephen C Teoh; Aideen C Hogan; Andrew D Dick; Richard W J Lee
Journal:  Am J Ophthalmol       Date:  2008-05-02       Impact factor: 5.258

8.  Fundus changes associated with Behçet's disease.

Authors:  L S Atmaca
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

9.  Uveitis in Behçet disease: an analysis of 880 patients.

Authors:  Ilknur Tugal-Tutkun; Sumru Onal; Rana Altan-Yaycioglu; Hasan Huseyin Altunbas; Meri Urgancioglu
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

10.  Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy.

Authors:  Hilal Eser Ozturk; Merih Oray; Ilknur Tugal-Tutkun
Journal:  Ocul Immunol Inflamm       Date:  2017-10-11       Impact factor: 3.070

View more
  2 in total

1.  Pattern and Visual Prognostic Factors of Behcet's Uveitis in Northwest Iran.

Authors:  Leila Alizadeh Ghavidel; Masood Bagheri; Farideh Mousavi; Leila Rezaei; Somayyeh Hazeri; Hesam-Sadat Hashemi
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

Review 2.  Behçet uveitis: Current practice and future perspectives.

Authors:  Shereen H Aboul Naga; Lameece Moustafa Hassan; Radwa T El Zanaty; Mohammad Refaat; Rana H Amin; Gaafar Ragab; Mahmoud M Soliman
Journal:  Front Med (Lausanne)       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.